Anti-Human CD34 (HB-34a) – Dylight ^® 488

Human endothelial vesicles

This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2-8°C Wet Ice

Blue Laser (493 nm)

HB-34a activity is directed against human CD34.

CD34 is a general marker of progenitor cells. CD34 is expressed on hematopoietic stem and progenitor cells as well as nonhematopoietic cell types including vascular endothelial progenitors, fibrocytes, mesenchymal stromal cells, interstitial cells, epithelial progenitors, muscle satellite cells, corneal keratocytes, vascular endothelial progenitors, mucosal dendritic cells, mast cells, and eosinophils.

CD34 is a transmembrane phosphoglycoprotein that contains a heavily sialylated extracellular domain, O- and N-linked glycosylation sites, a single transmembrane helix, and a cytoplasmic tail that contains PDZ-domain binding motifs ¹. CD34 interacts with L-selectin (CD62L), CrkL ¹, and integrin ² and also exerts a synergistic effect with inflammatory cytokines and chemokines ². CD34 functions in cell adhesion, regulation of cell differentiation and proliferation, trafficking of hematopoietic stem cells to niches within the bone marrow ¹, adult angiogenesis ³, inflammatory cell chemotaxis, and enhancement of the inflammatory response ². Additionally, CD34 is involved in cell migration, via the recruitment of lymphocytes to specialized high endothelial venules that line the secondary lymphoid organs, as well as T cell homing to these lymphoid organs ⁴.

CD34 is routinely used in clinical settings to identify and isolate hematopoietic stem and progenitor cells for bone marrow transplants to ensure rapid engraftment ¹, for example during hematopoietic reconstitution after myeloablative therapy in cancer patients ⁴. CD34+ autologous stem cells are also used as a novel therapeutic for ischemia with non-obstructive coronary arteries with coronary microvascular dysfunction ³. Clinical trials have investigated the use of CD34+ stem cell therapy in peripheral ischemia, nonischemic cardiomyopathy, myocardial infarction, ischemic stroke, and refractory angina. Additionally, CD34 expression is abnormally high in the intestine of inflammatory bowel disease (IBD) patients and is involved in the occurrence and development of IBD via its interactions with adhesion molecules as well as playing a role in the migration of immune cells to the inflammatory site ².

L-selectin, E-selectin

1. Sidney LE, Branch MJ, Dunphy SE, et al. Stem Cells. 32(6):1380-1389. 2014.
2. Li Z, Dong S, Huang S, et al. Front Physiol. 14:1144980. 2023.
3. Rai B, Shukla J, Henry TD, et al. Cells. 10(5):1137. 2021.
4. AbuSamra DB, Aleisa FA, Al-Amoodi AS, et al. Blood Adv. 1(27):2799-2816. 2017.